Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Filer	Latest Filing Date	Share-Type	Shares	Previously owned
Lenox Wealth Advisors, Llc	2021-04-26	Shares	780	780
Lenox Wealth Advisors, Llc	2021-04-26	Shares	780	780
Captrust Financial Advisors	2021-05-17	Shares	245	245
Captrust Financial Advisors	2021-05-17	Shares	245	245

PNK:ACUR

Acura Pharmaceuticals, Inc.

Market Cap

303.61K

Beta: 2.27

Volume Today

3

Avg: 6.20K

PE Ratio

−0.11

PFCF: −0.19

Institutional trades

Institutional Ownership

Current holdings institutionals